(Q33343208)

26 July 2017

title

Phase II trial of gemcitabine in advanced sarcomas (English)

1 reference

26 July 2017

main subject

phase II clinical trial

0 references

gemcitabine

1 reference

ChEBI release 2020-05-28

6

Evanthia Galanis

1 reference

26 July 2017

3

Michelle Mahoney

1 reference

26 July 2017

Scott Okuno

1

1 reference

26 July 2017

John Edmonson

series ordinal

2

1 reference

26 July 2017

Jan C Buckner

series ordinal

4

1 reference

26 July 2017

Stephen Frytak

series ordinal

5

1 reference

26 July 2017

language of work or name

English

0 references

publication date

1 June 2002

1 reference

26 July 2017

1 reference

26 July 2017

volume

94

1 reference

26 July 2017

issue

12

1 reference

26 July 2017

page(s)

3225-3229

1 reference

Gemcitabine in soft tissue or bone sarcoma resistant to standard chemotherapy: a phase II study

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10602

Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10602

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10602

Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10602

Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10602

Treatment of classical Kaposi's sarcoma with gemcitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10602

Phase II trial of gemcitabine in patients with pretreated advanced soft tissue sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10602

Needed: qualitative improvement in antisarcoma therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10602

inferred from DOI database lookup

7 January 2021

based on heuristic

Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10602

inferred from DOI database lookup

7 January 2021

based on heuristic

An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10602

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1002/CNCR.10602

1 reference

26 July 2017

1 reference